FPT-EUROPE
18.8.2021 08:32:11 CEST | Business Wire | Press release
FPT Europe, a subsidiary of the global technology services provider FPT Corporation, has announced the collaboration with innogy Czech, a leading energy company providing natural gas, electricity and heating solutions, as well as clean mobility solutions, to migrate the innogy Czech’s entire SAP R/3-based ERP infrastructure to the SaaS cloud. As the general contractor of the project, FPT will support the customer to migrate the current system to SAP S/4HANA as part of the greenfield approach. The goal is thus a complete redesign of the Enterprise Resource Planning (ERP), which is business-critical for innogy Czech, including streamlining and simplifying all processes automated in the system. FPT is responsible for the entire scope of the project, from consulting to planning and implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210817005685/en/
"We entrusted FPT with the upgrade of our SAP system to S/4 HANA because of the company’s expertise, technical capabilities and years of experience in the industry," says Miloš Dušek, Senior Manager of Corporate Applications at innogy Ceska republika. "The project is of great strategic importance for innogy. FPT has proven to be a reliable strategic partner for us and has put together a qualified team to ensure that the first part of the project will be delivered successfully by the end of 2021."
Lighthouse project in the growing market of SAP S/4HANA
The aim of the project is to replace the current SAP ERP system used by innogy Czech in version R/3 ERP Central Component 6.0 EhP 8, which has so far been based on HANA DB2, with S/4HANA Private Cloud Edition. "SAP made an announcement that the company will end the support for its on-premises solutions by 2027. Many companies therefore would want to migrate their system to S/4 HANA in a timely manner," explains Andy Do, Deputy Director/Head of Delivery at FPT Europe. "FPT has strong expertise and many years of experience in cloud migration as well as SAP migration projects, but the project with innogy Czech can be considered as one of the largest end-to-end S/4HANA migration projects for us. It offers FPT a great opportunity to position ourselves as a trusted partner in the field of SAP S/4HANA migration."
The scope of work mentioned above will be applied for 5 companies within innogy Czech Republic group, including innogy Ceska republika a.s., innogy Zakaznicke sluzby, s.r.o., innogy Energie, s.r.o., innogy Energo, s.r.o. and innogy Energetika Plhov-Nachod, s.r.o.
FPT has more than 20 years of experience in providing services related to SAP. With a pool of more than 300 functional and 250 technical consultants, FPT has successfully implemented and rolled out SAP systems for customers in Southeast Asia, Japan and Europe. With SAP S/4HANA, FPT offers a wide range of services such as development, implementation and rollout. FPT also offers its own solutions in the field of Application Managed Services (AMS). FPT’s services in the areas of SAP migration, SAP customization, SAP rollout and SAP Automation Testing help its customers assure smooth and efficient implementation of SAP S/4HANA.
About FPT Europe
FPT Europe, based in Essen, Germany is a part of FPT Corporation - a technology and IT services provider headquartered in Vietnam with nearly US$2 billion in revenue and 36,000 employees. Being a pioneer in digital transformation, the company delivers world-class services in Smart factory, Digital platforms, RPA, AI, IoT, Data Analytics, Mobility, Cloud, Managed Services, Testing. FPT Software has served over 700 customers worldwide, 100 of which are Fortune 500 companies in the industries of Aerospace & Aviation, Automotive, Banking and Finance, Communications, Media and Services, Logistics & Transportation, Utilities, Consumer Packaged Goods, Healthcare, Manufacturing, Public sector, Technology and so on. Established in 2012, FPT Europe has become technology partners of 50 leading companies including Siemens, RWE, Allianz, Schaeffler, Airbus, Carlsberg and many more. For other information, please visit: www.fpt-europe.de
About innogy Czech
innogy Česká republika is a leading energy company in the Czech Republic owned by the largest Hungarian energy group MVM. innogy supplies 1.6 million customers with energy and energy-related innovative services. First class customer service is provided by own call centres and a chain of customer service centres. In addition to gas and electricity supplies, innogy produces heat and electricity in heating plants across the country with an annual heat production of 900,000 GJ. Aside from the core business, innogy focuses on clean mobility, photovoltaics and energy management services. With a nationwide network of 60+ filling stations, own CNG technology production and more than 10 million kg CNG sold annually, innogy is a strong market leader. innogy is also building up a solid position in the fast-growing solar power plants market. The company employs 1,500 highly skilled people and the innogy brand is known to more than 90% of the Czech population.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210817005685/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom